<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Weickert P</submitter><funding>European Research Council</funding><funding>Deutsche Forschungsgemeinschaft (German Research Foundation)</funding><funding>European Molecular Biology Organization (EMBO)</funding><funding>Alfried Krupp von Bohlen und Halbach-Stiftung (Alfried Krupp von Bohlen und Halbach Foundation)</funding><pagination>352</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9867749</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>DNA-protein crosslinks (DPCs) are pervasive DNA lesions that are induced by reactive metabolites and various chemotherapeutic agents. Here, we develop a technique for the Purification of x-linked Proteins (PxP), which allows identification and tracking of diverse DPCs in mammalian cells. Using PxP, we investigate DPC repair in cells genetically-engineered to express variants of the SPRTN protease that cause premature ageing and early-onset liver cancer in Ruijs-Aalfs syndrome patients. We find an unexpected role for SPRTN in global-genome DPC repair, that does not rely on replication-coupled detection of the lesion. Mechanistically, we demonstrate that replication-independent DPC cleavage by SPRTN requires SUMO-targeted ubiquitylation of the protein adduct and occurs in addition to proteasomal DPC degradation. Defective ubiquitin binding of SPRTN patient variants compromises global-genome DPC repair and causes synthetic lethality in combination with a reduction in proteasomal DPC repair capacity.</pubmed_abstract><journal>Nature communications</journal><pubmed_title>SPRTN patient variants cause global-genome DNA-protein crosslink repair defects.</pubmed_title><pmcid>PMC9867749</pmcid><funding_grant_id>801750</funding_grant_id><funding_grant_id>Alfried Krupp Prize</funding_grant_id><funding_grant_id>YIP4644</funding_grant_id><funding_grant_id>Project ID 213249687 - SFB 1064</funding_grant_id><pubmed_authors>Weickert P</pubmed_authors><pubmed_authors>Gotz MJ</pubmed_authors><pubmed_authors>Forne I</pubmed_authors><pubmed_authors>Zhao S</pubmed_authors><pubmed_authors>Durauer S</pubmed_authors><pubmed_authors>Imhof A</pubmed_authors><pubmed_authors>Stingele J</pubmed_authors><pubmed_authors>Li HY</pubmed_authors><pubmed_authors>Acampora AC</pubmed_authors><pubmed_authors>Cordes J</pubmed_authors><pubmed_authors>Yaneva D</pubmed_authors></additional><is_claimable>false</is_claimable><name>SPRTN patient variants cause global-genome DNA-protein crosslink repair defects.</name><description>DNA-protein crosslinks (DPCs) are pervasive DNA lesions that are induced by reactive metabolites and various chemotherapeutic agents. Here, we develop a technique for the Purification of x-linked Proteins (PxP), which allows identification and tracking of diverse DPCs in mammalian cells. Using PxP, we investigate DPC repair in cells genetically-engineered to express variants of the SPRTN protease that cause premature ageing and early-onset liver cancer in Ruijs-Aalfs syndrome patients. We find an unexpected role for SPRTN in global-genome DPC repair, that does not rely on replication-coupled detection of the lesion. Mechanistically, we demonstrate that replication-independent DPC cleavage by SPRTN requires SUMO-targeted ubiquitylation of the protein adduct and occurs in addition to proteasomal DPC degradation. Defective ubiquitin binding of SPRTN patient variants compromises global-genome DPC repair and causes synthetic lethality in combination with a reduction in proteasomal DPC repair capacity.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-27T01:41:01.812Z</modification><creation>2025-02-19T03:00:22.929Z</creation></dates><accession>S-EPMC9867749</accession><cross_references><pubmed>36681662</pubmed><doi>10.1038/s41467-023-35988-1</doi></cross_references></HashMap>